GlassScriptPhysician profile
Megan Seibert Cherry
NPI 1962667238
$136,887.61
in general payments reported to CMS, 2019-2025
42 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $17K · 2021: $4,279 · 2022: $17K · 2023: $26K · 2024: $22K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $4,670 · Travel and Lodging: $3,922 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,750.00 |
| Food and Beverage | $4,670.08 |
| Travel and Lodging | $3,922.30 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68,515.36 | 2019-2025 | Botox, Kybella, Rinvoq |
| Allergan, INC. | $60,834.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $785.86 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $674.28 | 2019-2024 | Duobrii, Arazlo, Jublia |
| Galderma Laboratories, L.P. | $568.52 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Leo Pharma INC. | $453.35 | 2019-2025 | Anzupgo, Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $451.60 | 2019-2025 | Winlevi, Absorica Ld, Blu-U |
| Incyte Corporation | $444.31 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $362.72 | 2019-2025 | |
| Pfizer INC. | $349.28 | 2019-2024 | |
| Janssen Biotech, INC. | $285.94 | 2019-2024 | Tremfya |
| Journey Medical Corporation | $279.43 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.03 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $263.39 | 2019-2022 | |
| Amgen INC. | $221.77 | 2019-2025 | Otezla, Otezla |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.